1,4-dihydroxy-4a,5,6,7,8,8a-hexahydroquinoxaline-2,3-dione is a **synthetic compound** that exhibits interesting properties, making it relevant in various research areas. Let's break down its structure, potential uses, and why it's important:
**Structure:**
* **Core:** The core structure is a **quinoxaline ring**, which is a bicyclic molecule containing two nitrogen atoms and two fused benzene rings.
* **Substitutions:** The compound is characterized by the presence of two hydroxyl (-OH) groups at positions 1 and 4 and a **hexahydro** prefix indicating that six of the ring's carbons have hydrogen atoms attached. It also has two ketone groups (C=O) at positions 2 and 3.
**Properties:**
* **Antioxidant:** This compound has demonstrated antioxidant properties, meaning it can neutralize harmful free radicals in the body. This makes it a potential candidate for research related to aging, inflammation, and disease prevention.
* **Anti-inflammatory:** It has been shown to exhibit anti-inflammatory properties, suggesting possible applications in the treatment of inflammatory conditions like arthritis.
* **Biological Activity:** Research indicates it may have other biological activities, such as antimicrobial and anticancer properties, though further investigation is required.
**Why it's important for research:**
1. **Potential therapeutic applications:** Its antioxidant and anti-inflammatory properties make it a potential candidate for developing new drugs to treat various diseases, including inflammatory disorders, oxidative stress-related conditions, and possibly cancer.
2. **Novel drug discovery:** It serves as a valuable lead compound for researchers to modify and synthesize new derivatives with potentially enhanced pharmacological activity and improved drug properties.
3. **Chemical probe for biological studies:** Its unique chemical structure can be used as a tool to understand various biological processes, such as the role of antioxidants in cellular defense mechanisms or the mechanisms of inflammation.
4. **Drug delivery:** Its structure might allow for modification to become a drug delivery system for other therapeutic agents, making it a potential platform for targeted drug delivery.
**Important Note:** The compound's actual impact and applications in research are still under investigation. More research is needed to fully understand its efficacy, safety, and potential for therapeutic use.
While 1,4-dihydroxy-4a,5,6,7,8,8a-hexahydroquinoxaline-2,3-dione shows promising characteristics, it's crucial to remember that the research journey is long and complex. Further studies are required to translate its potential into effective treatments and applications.
ID Source | ID |
---|---|
PubMed CID | 2729826 |
CHEMBL ID | 1352724 |
CHEBI ID | 108255 |
SCHEMBL ID | 20777962 |
Synonym |
---|
1,4-dihydroxy-octahydro-quinoxaline-2,3-dione |
MLS000589383 , |
smr000212754 |
SR-01000643127-1 |
CHEBI:108255 |
AKOS000550189 |
1,4-dihydroxy-4a,5,6,7,8,8a-hexahydroquinoxaline-2,3-dione |
HMS2554M21 |
CCG-54005 |
FT-0606878 |
286409-64-1 |
1,4-dihydroxyoctahydroquinoxaline-2,3-dione |
STL321942 |
AKOS022140350 |
CHEMBL1352724 |
Q27186951 |
DTXSID10369615 |
1,4-dihydroxyhexahydroquinoxaline-2,3(1h,4h)-dione |
1,4-dihydroxyperhydroquinoxaline-2,3-dione |
1,4-dihydroxy-decahydroquinoxaline-2,3-dione |
BRD-A36938160-001-08-5 |
SCHEMBL20777962 |
CS-0358043 |
Class | Description |
---|---|
organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.6310 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 14.0919 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 89.1251 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 7.9433 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 20.8584 | 0.1337 | 25.4129 | 89.1251 | AID588795; AID720498 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 112.2020 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.17) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |